Drug Trial Radar · NCT07474727
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Apr 29, 2026
Primary completion
Sep 30, 2027
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- Multitude Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open, multi-center, phase II study, aiming to evaluate the safety, tolerability and efficacy of AMT-676 combined with 5-fluorouracil, leucovorin, bevacizumab (or cetuximab) in participants with advanced colorectal cancer, and to assess the PK(Pharmacokinetic) characteristics and immunogenicity of AMT-676.
Conditions
- Colorectal Cancer
Interventions
AMT-676Drug
Patients will get different dose levels treatment of AMT-676. AMT-676 will be Administered as an intravenous (IV) infusion every 2 weeks (Q2W) .
5-FUDrug
5-FU 400 mg/m\^2 IV bolus on day 1, followed by 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46-48 hours) IV continuous infusion, q2w
LeucovorinDrug
Leucovorin 400 mg/m\^2 IV day 1, q2w
BevacizumabDrug
Bevacizumab 5 mg/kg IV, day 1
CetuximabDrug
Cetuximab 500 mg/m\^2 IV over 2 hours, day 1, q2w
IrinotecanDrug
Irinotecan 180 mg/m\^2 IV, day 1
OxaliplatinDrug
Oxaliplatin 85 mg/m\^2 IV, day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- AE & SAETime frame: 30 days after the last treatment
- MTDTime frame: 28 days after first dose
- DLTsTime frame: 28 days after first dose
- ORRTime frame: through study completion, an average of 18 months
- PFSTime frame: through study completion, an average of 18 months
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
Guangxi Medical University Cancer Hospital
Nanning, Gaungxi, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Not yet recruiting
Wuhan Union Hospital of China
Wuhan, Hubei, China · Not yet recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Not yet recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Liaoning Cancer Hospital & Institute
Shengyang, Liaoning, China · Not yet recruiting
Shandong Cancer Hospital and Institute
Jinan, Shandong, China · Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Not yet recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Not yet recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.